€80k - €170kFirst value signal
Registered business in Leuven · BE. Official registry identity, filed financial evidence and a public indicative value curve on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsThe historical curve shows where this company stood. Unlock what holds back value today, what it could be in five years and which actions matter now.
Free account · private workspace
Public filings are a starting point. Accounts, owner context and method review narrow the range and make it useful for a sale, financing or transfer.
Own this company? Claim and manage the profileYou have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for Tijdschrift voor Geneeskunde combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
Express interest and ask Upswitch to discreetly sound out the owner. We review every request before making contact.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Operating as a business in NACE sector 58130, Tijdschrift voor Geneeskunde is registered in Leuven, Belgium. The company was founded in 1962, incorporated as a Vereniging zonder winstoogmerk.
Tijdschrift voor Geneeskunde is listed in Belgian Crossroads Bank for Enterprises (KBO) under registry number 0410801631 and VAT number BE0410801631. This profile consolidates Kbo Open Data, NBB/CBSO annual accounts into one indexable company dossier.
Companies in this NACE 58130 band file annual accounts with NBB/CBSO.
Across the 2024-2025 window revenue has moderated, moving from €175,825 to €154,659. EBITDA for 2025 comes in at -€110,085.
A public indicative value curve is available for Tijdschrift voor Geneeskunde, based on filed company accounts. A free account unlocks the five-year outlook and concrete actions to increase value.
The most recent annual filing covers 2025 (period end 2025-12-31).
This page is refreshed whenever new regulator-filed data for Tijdschrift voor Geneeskunde becomes available, consolidated into a single audit-grade view.
Public regulator-filed figures across 2 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Dec 2025 | €154,659 | -€110,085 | €894,790 | €791,357 | - |
| 202431 Dec 2024 | €175,825 | -€198,315 | €1,021,672 | €912,891 | - |
Tijdschrift voor Geneeskunde was founded in 1962 and is registered with Belgian Crossroads Bank for Enterprises (KBO), incorporated as a Vereniging zonder winstoogmerk.
Tijdschrift voor Geneeskunde is registered under NACE 58130: NACE 58130. That places the business within the Belgian cluster for this activity.
According to the company registry, Tijdschrift voor Geneeskunde is based in Leuven, BE.
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-12-31), publicly available via Belgian Crossroads Bank for Enterprises (KBO).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for Tijdschrift voor Geneeskunde may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
Public profiles for peers in the same industry and country. Click through to compare filings and indicative valuations.
